206 related articles for article (PubMed ID: 23144154)
1. Interleukin-6 and oncostatin M are elevated in liver disease in conjunction with candidate hepatocellular carcinoma biomarker GP73.
Liang H; Block TM; Wang M; Nefsky B; Long R; Hafner J; Mehta AS; Marrero J; Gish R; Norton PA
Cancer Biomark; 2012; 11(4):161-71. PubMed ID: 23144154
[TBL] [Abstract][Full Text] [Related]
2. A study of diagnostic value of golgi protein GP73 and its genetic assay in primary hepatic carcinoma.
Shi Y; Chen J; Li L; Sun Z; Zen L; Xu S; Zhang Y; Zhang L
Technol Cancer Res Treat; 2011 Jun; 10(3):287-94. PubMed ID: 21517136
[TBL] [Abstract][Full Text] [Related]
3. Serum Golgi protein 73 is not a suitable diagnostic marker for hepatocellular carcinoma.
Liu T; Yao M; Liu S; Wang L; Wang L; Hou J; Ma X; Jia J; Zhao J; Zhuang H; Lu F
Oncotarget; 2017 Mar; 8(10):16498-16506. PubMed ID: 28157705
[TBL] [Abstract][Full Text] [Related]
4. [Expression of miR-212 and miR-132 in serum of patients with primary liver cancer and their targeted regulation of GP73].
Sha M; Wang B; Xiao L; Ye J; Wang J; Luan ZY
Zhonghua Gan Zang Bing Za Zhi; 2017 Dec; 25(12):920-926. PubMed ID: 29325293
[No Abstract] [Full Text] [Related]
5. Evaluation of circulating Transforming growth factor-beta1, Glypican-3 and Golgi protein-73 mRNAs expression as predictive markers for hepatocellular carcinoma in Egyptian patients.
Ibrahim GH; Mahmoud MA; Aly NM
Mol Biol Rep; 2013 Dec; 40(12):7069-75. PubMed ID: 24186850
[TBL] [Abstract][Full Text] [Related]
6. Development and potential application of a simultaneous multiplex assay of Golgi protein 73 and alpha-fetoprotein for hepatocellular carcinoma diagnosis.
Xiao J; Long F; Peng T; Hu LB; Cai H; Chen R; Chen WL
Eur Rev Med Pharmacol Sci; 2019 Apr; 23(8):3302-3310. PubMed ID: 31081083
[TBL] [Abstract][Full Text] [Related]
7. Clinical significance and expression of serum Golgi protein 73 in primary hepatocellular carcinoma.
Jiao C; Cui L; Piao J; Qi Y; Yu Z
J Cancer Res Ther; 2018; 14(6):1239-1244. PubMed ID: 30488837
[TBL] [Abstract][Full Text] [Related]
8. The diagnostic value of golgi protien-73 and DICKKOPF-1 in hepatocellular carcinoma.
ElZefzafy WM; Hussien M; Mohmmed ZAZ; Abd Elbaky NM
J Immunoassay Immunochem; 2021 Mar; 42(2):174-187. PubMed ID: 33284721
[TBL] [Abstract][Full Text] [Related]
9. GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma.
Marrero JA; Romano PR; Nikolaeva O; Steel L; Mehta A; Fimmel CJ; Comunale MA; D'Amelio A; Lok AS; Block TM
J Hepatol; 2005 Dec; 43(6):1007-12. PubMed ID: 16137783
[TBL] [Abstract][Full Text] [Related]
10. [Detection and evaluation of serum GP73, a resident Golgi glycoprotein, as a marker in diagnosis of hepatocellular carcinoma].
Zhao XY; Li N; Ding HG; Jiang FF
Zhonghua Zhong Liu Za Zhi; 2010 Dec; 32(12):943-5. PubMed ID: 21223806
[TBL] [Abstract][Full Text] [Related]
11. GP73, a resident Golgi glycoprotein, is sensibility and specificity for hepatocellular carcinoma of diagnosis in a hepatitis B-endemic Asian population.
Hu JS; Wu DW; Liang S; Miao XY
Med Oncol; 2010 Jun; 27(2):339-45. PubMed ID: 19399652
[TBL] [Abstract][Full Text] [Related]
12. The Value of GPC3 and GP73 in Clinical Diagnosis of Hepatocellular Carcinoma.
Jing JS; Ye W; Jiang YK; Ma J; Zhu MQ; Ma JM; Zhou H; Yu LQ; Yang YF; Wang SC
Clin Lab; 2017 Nov; 63(11):1903-1909. PubMed ID: 29226636
[TBL] [Abstract][Full Text] [Related]
13. The response of Golgi protein 73 to transcatheter arterial chemoembolization in patients with hepatocellular carcinoma may relate to the influence of certain chemotherapeutics.
Pan J; Zhang YF; Yang HY; Xu HF; Lu X; Sang XT; Zhong SX; Mao YL
Hepatobiliary Pancreat Dis Int; 2015 Aug; 14(4):406-12. PubMed ID: 26256086
[TBL] [Abstract][Full Text] [Related]
14. The predictive value of Golgi protein 73 in differentiating benign from malignant liver tumors.
Bröker ME; Ijzermans JN; Witjes CD; van Vuuren HJ; de Man RA
PLoS One; 2014; 9(7):e100187. PubMed ID: 25033446
[TBL] [Abstract][Full Text] [Related]
15. [Clinical application of serum Golgi protein 73 in the diagnosis and progress of hepatocellular carcinoma].
Zhao Y; Li Y; Hu B; He X; Huang J; Zhan M; Lu L
Zhonghua Yi Xue Za Zhi; 2014 Feb; 94(5):390-2. PubMed ID: 24746091
[TBL] [Abstract][Full Text] [Related]
16. Multiple lectin assays for detecting glyco-alteration of serum GP73 in liver diseases.
Jiang K; Shang S; Li W; Guo K; Qin X; Zhang S; Liu Y
Glycoconj J; 2015 Dec; 32(9):657-64. PubMed ID: 26342810
[TBL] [Abstract][Full Text] [Related]
17. Preparation and characterization of anti-GP73 monoclonal antibodies and development of double-antibody sandwich ELISA.
Li QW; Chen HB; Li ZY; Shen P; Qu LL; Gong LL; Xu HP; Pang L; Si J
Asian Pac J Cancer Prev; 2015; 16(5):2043-9. PubMed ID: 25773808
[TBL] [Abstract][Full Text] [Related]
18. Identification and characterization of monoclonal antibodies against GP73 for use as a potential biomarker in liver cancer screening and diagnosis.
Zhang Y; Xi Y; Fang J; Luo S; Wilson JJ; Huang RP
J Immunoassay Immunochem; 2016; 37(4):390-406. PubMed ID: 27088654
[TBL] [Abstract][Full Text] [Related]
19. Sublingual vein parameters, AFP, AFP-L3, and GP73 in patients with hepatocellular carcinoma.
Zhao J; Guo LY; Yang JM; Jia JW
Genet Mol Res; 2015 Jun; 14(2):7062-7. PubMed ID: 26125916
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic and prognostic validity of Golgi protein 73 in hepatocellular carcinoma.
Ozkan H; Erdal H; Tutkak H; Karaeren Z; Yakut M; Yüksel O; Köklü S
Digestion; 2011; 83(1-2):83-8. PubMed ID: 21042019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
